Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Risk stratification in MDS

Hege Garelius • 9 Jun 2022
EHA 2022
Myelodysplastic Syndromes

Hege Garelius, MD, Sahlgrenska University Hospital, Göteborg, Sweden, comments on risk stratification in myelodysplastic syndromes (MDS), highlighting the importance of incorporating mutations in these classifications. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Hege Garelius

1:34
Perspectives on the management of low and high-risk MDS
Hege Garelius • 9 Jun 2022
0:33
Unmet needs in MDS: treating relapse after alloHSCT & TP53-mutated disease
Hege Garelius • 9 Jun 2022
1:48
The impact of ESAs in lower-risk MDS
Hege Garelius • 9 Jun 2022

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals